Table 1. Major Characteristics of Fifteen Controlled Researches on Peritoneal Carcinomatosis (PC) from Colorectal Cancer (CRC) Treated with Cytoreductive Surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) versus Surgery alone with Systemic Chemotherapy (SC) and/or Early Postoperative Intraperitoneal Chemotherapy (EPIC).
| Author/ Year/ Country | Participating Institutions |
Study Period | Design | Level of Evidence | Number of CRC PC | Treatment strategy | |
|---|---|---|---|---|---|---|---|
| HIPEC group | Control group | ||||||
| Chua TC/ 2009/ Australia [34] |
2 | 1997-2008 | retrospective | IIb | 15 (15/33) | CRS+HIPEC 7 pts; HIPEC: MMC (10-20 mg/m2) for 90 min at 42°C using the closed abdomen technique. No EPIC. SC: FOLFOX and Bevacizumab |
SC 8 pts SC: FOLFOX and Bevacizumab No HIPEC No EPIC |
| Chua TC/ 2011/ Australia [15] |
3 | 1988-2009 | retrospective | IIa | 294 (294/294) | CRS+HIPEC+SC 110 pts HIPEC: MMC (10-20 mg/m2) for 90 min at 42°C using the Coliseum technique. No EPIC SC: 5-FU + LV; 5-FU + LV or CBP with L-OHP or CPT-11; or Regimen 2 + BEV, C225, or PAN |
Surgery and/or SC 184 pts SC: 5-FU + LV; 5-FU + LV or CBP with L-OHP or CPT-11; or Regimen 2 + BEV, C225, or PAN No EPIC No HIPEC |
| Chua TC/ 2013/ Australia [26] |
1 | 1996-2011 | prospective | IIa | 75 (75/98) | CRS+HIPEC with/without EPIC 75pts HIPEC: MMC (10–12.5 mg/m2) or L-OHP (460 mg/m2) for 90 min at 42°C using the closed abdomen technique; Before starting HIEPC, oxaliplatin, 5-FU (400 mg/m2) and LV (20 mg/m2) by intravenous perfusion. EPIC: 5-FU (650–800 mg/m2/d) on Day 1-5 after surgery SC (not reported) |
EPIC alone 23 pts EPIC: 5-FU (650–800 mg/m2/d) on Day 1-5 after surgery SC (not reported) No HIPEC |
Note: CRC: colorectal cancer; PC: peritoneal carcinomatosis; Pts: patients; MMC: mitomycin C; DDP: cisplatin; FU: fluorouracil; LV: leucovorin; L-OHP: oxaliplatin; CPT-11: irinotecan; Cap: capecitabine; C225: cetuximab; CPT: camptothecin; BEV: bevacizumab; DXL: docetaxel; CBP: carboplatin; PAN: panitumumab;